Status:

COMPLETED

A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects

Lead Sponsor:

Pfizer

Conditions:

Obesity

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

PHASE3

Brief Summary

To evaluate the effect of 6-month administration of CP-945,598 on: * weight loss and waist circumference, * blood pressure, cholesterol, glucose * other biochemical variables like insulin, leptin, gh...

Eligibility Criteria

Inclusion

  • Male and/or female subjects without clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurements, 12 lead ECG and clinical laboratory tests
  • Body Mass Index (BMI) ³30 and \<40 kg/m2, for subjects with no additional
  • co morbidities; BMI ³27 kg/m2 and \<40 kg/m2, for subjects with co morbidities \[history of essential hypertension and/or dyslipidemia defined as high LDL (³160 mg/dL) or high total cholesterol (³240 mg/dL)\];

Exclusion

  • Subjects with resting sitting systolic blood pressure of 140 mmHg or greater or diastolic blood pressure of 90 mmHg or greater.
  • Subjects with type 2 diabetes or fasting blood glucose concentration ³126 mg/dL;
  • Subjects with a history of eating disorders like anorexia nervosa or bulimia nervosa
  • Subjects on prescription and non-prescription appetite or weight modifying drugs

Key Trial Info

Start Date :

March 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2005

Estimated Enrollment :

282 Patients enrolled

Trial Details

Trial ID

NCT00134199

Start Date

March 1 2005

End Date

November 1 2005

Last Update

August 12 2009

Active Locations (15)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (15 locations)

1

Pfizer Investigational Site

Clearwater, Florida, United States, 33761

2

Pfizer Investigational Site

Kissimmee, Florida, United States, 34741

3

Pfizer Investigational Site

Orlando, Florida, United States, 32809

4

Pfizer Investigational Site

Lexington, Kentucky, United States, 40509